SUBACROMIAL INJECTIONS OF HYDROLYZED COLLAGEN FOR THE TREATMENT OF ROTATOR CUFF TENDINOPATHY

The efficacy of hydrolyzed collagen in pain reduction and functional recovery of patients with rotator cuff tendinopathy.

Introduction: The purpose of the present prospective multicenter observational study was to evaluate the efficacy and safety of a new infiltration device (CHondroGrid, Bioteck S.p.A, Arcugnano, Italy) based on hydrolyzed collagen in the treatment of rotator cuff tendinopathy.

Materials and Methods: Seventy-one patients (53.3 ± 11.6 years) with rotator cuff tendinopathy were treated in 2021 with two subacromial injections of CHondroGrid 13 ± 2.9 days apart. The outcomes measured were visual analog scale (VAS) score (in motion, overnight, and at rest), Constant Score, Simple Shoulder Test, and patient satisfaction. The outcome variables were measured before each injection, at 1 month and at 6 months after the last injection.

Results: The treatment was significantly effective from the first injection and up to the 6-month. follow-up. At the last follow-up, the VAS score at movement had improved by 71% (P < .001), while the VAS score at rest and during the night had improved by 91% and 87%, respectively (P < .001). The Constant Score and Simple Shoulder Test improved by 32% and 61%, respectively (P < .001). No adverse events were reported.

Conclusions: CHondroGrid was found to be a safe and effective treatment for pain relief and functional recovery of rotator cuff tendinopathy. functional recovery of rotator cuff tendinopathy.

PRODUCTS USED: CHONDROGRID, CHG-004

JSES international
799-804